Vertex's Pain Drug Failures and Leadership Changes Shake Investor Confidence
TL;DR Summary
Vertex Pharmaceuticals announced that its experimental pain drug VX-993 failed to outperform placebo in a Phase 2 trial, leading to the discontinuation of its development as a single-agent for acute pain, though the company will continue testing it for chronic nerve pain in diabetic patients.
- Vertex next-generation pain candidate fails Phase 2 trial statnews.com
- Vertex Stock Falls After Pain-Drug Setback, Despite Stronger Earnings The Wall Street Journal
- Vertex Stock Tumbles 15% After Strong Earnings. What’s Spooking Investors. Barron's
- Vertex’s top scientist Altshuler to retire, next-generation pain drug fails Endpoints News
- Vertex's trial failure, scrapped study cloud pain drug push; shares slump Reuters
Reading Insights
Total Reads
0
Unique Readers
2
Time Saved
1 min
vs 2 min read
Condensed
79%
211 → 45 words
Want the full story? Read the original article
Read on statnews.com